E-LIB Suche - Ergebnisse für: Lahuerta, A

1

The genomic profiling of high-risk smoldering myeloma patie..:

Medina-Herrera, A. ; Vazquez, I. ; Cuenca, I....
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

2

Phase III evaluating the addition of fulvestrant (F) to ana..:

Ruíz-Borrego, Manuel ; Guerrero-Zotano, Angel ; Bermejo, Begoña...
Breast Cancer Research and Treatment. 177 (2019) 1 - p. 115-125 , 2019

Link: https://doi.org/10.1007/..

3

Papain‐treated panels are a simple method for the identific..:

Carreño‐Tarragona, G. ; Cedena, T. ; Montejano, L....
Transfusion Medicine. 29 (2018) 3 - p. 193-196 , 2018

Link: https://doi.org/10.1111/..

4

Initiative To Obtain Advanced Therapeutic Outcomes In Multi..:

Blade, J ; Calleja, M ; Lahuerta, J...
Value in Health. 20 (2017) 9 - p. A460 , 2017

Link: https://doi.org/10.1016/..

5

AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGA..:

Jiménez Ubieto, A. ; Grande, C. ; Caballero, D....
Hematological Oncology. 35 (2017) S2 - p. 221-222 , 2017

Link: https://doi.org/10.1002/..

6

Bortezomib and thalidomide maintenance after stem cell tran..:

Rosiñol, L ; Oriol, A ; Teruel, A I...
Leukemia. 31 (2017) 9 - p. 1922-1927 , 2017

Link: https://doi.org/10.1038/..

7

Toxicity and efficacy of busulfan and fludarabine myeloabla..:

De La Serna, J ; Sanz, J ; Bermúdez, A...
Bone Marrow Transplantation. 51 (2016) 7 - p. 961-966 , 2016

Link: https://doi.org/10.1038/..

8

Differentiation stage of myeloma plasma cells: biological a..:

Paiva, B ; Puig, N ; Cedena, M T...
Leukemia. 31 (2016) 2 - p. 382-392 , 2016

Link: https://doi.org/10.1038/..

9

Pretransplant induction with VTD (Bortezomib/Thalidomide/De..:

Rosiñol, L. ; Rosiñol, L. ; Oriol, A....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e49-e50 , 2015

Link: https://doi.org/10.1016/..

10

Flow Cytometry for Minimal Residual Disease:

Paiva, B. ; Vidriales, M.B. ; Puig, N....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e5 , 2015

Link: https://doi.org/10.1016/..

11

Autologous Activated and Expanded Natural Killer Cells Dest..:

Leivas, A. ; Risueño, R.M. ; Pérez-Martínez, A....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e245-e246 , 2015

Link: https://doi.org/10.1016/..

12

Treatment of renal failure in patients with newly diagnosed..:

Rosiñol, L. ; Oriol, A. ; Blanchard, M.J....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e256-e257 , 2015

Link: https://doi.org/10.1016/..

13

Multiple Infusions of Autologous Activated and Expanded Nat..:

Leivas, A. ; Pérez-Martínez, A. ; Blanchard, M.J....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e297-e298 , 2015

Link: https://doi.org/10.1016/..

14

Outcome of Patients with Extramedullary Plasmacytomas (EMPs..:

Jiménez, R. ; Rosiñol, L. ; Teruel, A.I....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e100 , 2015

Link: https://doi.org/10.1016/..

15

Patterns of relapse and outcome of elderly multiple myeloma..:

López, A. ; Mateos, M.-V. ; Oriol, A....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. e278-e280 , 2015

Link: https://doi.org/10.1016/..